ArticlePloS one2014
Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Myeloid-Derived Suppressor Cells in Inflammatory Arthritis.International journal of molecular sciences · 2026Review
- Diverse functions of myeloid-derived suppressor cells in autoimmune diseases.Immunologic research · 2024Review
- MDSCs use a complex molecular network to suppress T-cell immunity in a pulmonary model of fungal infection.Frontiers in cellular and infection microbiology · 2024Article
- The immunosuppressive activity of myeloid-derived suppressor cells in murine Paracoccidioidomycosis relies on Indoleamine 2,3-dioxygenase activity and Dectin-1 and TLRs signaling.Scientific reports · 2023Article
- Myeloid-derived suppressor cells are associated with impaired Th1 and Th17 responses and severe pulmonary paracoccidioidomycosis which is reversed by anti-Gr1 therapy.Frontiers in immunology · 2023Article
- Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease.International journal of molecular sciences · 2022Review
- Aging Affects the Role of Myeloid-Derived Suppressor Cells in Alloimmunity.Frontiers in immunology · 2022Review
- The emerging role of regulatory cell-based therapy in autoimmune disease.Frontiers in immunology · 2022Review
- Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.Frontiers in immunology · 2022Review
- Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases.Cellular and molecular life sciences : CMLS · 2021Review
- Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.Inflammopharmacology · 2021Review
- Article
- Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.Cellular immunology · 2021Review
- Review
- Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.Frontiers in immunology · 2021Article
- Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine.Open biology · 2020Review
- Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase.Arthritis research & therapy · 2020Article
- Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing.Frontiers in oncology · 2019Article
- Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.Frontiers in immunology · 2019Review
- Administration of cytokine-induced myeloid-derived suppressor cells ameliorates renal fibrosis in diabetic mice.Stem cell research & therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMyeloid-derived suppressor cells (MDSCs) are innate immune cells capable of suppressing T-cell responses. We previously reported the presence of MDSCs with a granulocytic phenotype in the synovial fluid (SF) of mice with proteoglycan (PG)-induced arthritis (PGIA), a T cell-dependent autoimmune model of rheumatoid arthritis (RA). However, the limited amount of SF-MDSCs precluded investigations into their therapeutic potential. The goals of this study were to develop an in vitro method for generating MDSCs similar to those found in SF and to reveal the therapeutic effect of such cells in PGIA.
methodsMurine bone marrow (BM) cells were cultured for 3 days in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), and granulocyte colony-stimulating factor (G-CSF). The phenotype of cultured cells was analyzed using flow cytometry, microscopy, and biochemical methods. The suppressor activity of BM-MDSCs was tested upon co-culture with activated T cells. To investigate the therapeutic potential of BM-MDSCs, the cells were injected into SCID mice at the early stage of adoptively transferred PGIA, and their effects on the clinical course of arthritis and PG-specific immune responses were determined.
resultsBM cells cultured in the presence of GM-CSF, IL-6, and G-CSF became enriched in MDSC-like cells that showed greater phenotypic heterogeneity than MDSCs present in SF. BM-MDSCs profoundly inhibited both antigen-specific and polyclonal T-cell proliferation primarily via production of nitric oxide. Injection of BM-MDSCs into mice with PGIA ameliorated arthritis and reduced PG-specific T-cell responses and serum antibody levels.
conclusionsOur in vitro enrichment strategy provides a SF-like, but controlled microenvironment for converting BM myeloid precursors into MDSCs that potently suppress both T-cell responses and the progression of arthritis in a mouse model of RA. Our results also suggest that enrichment of BM in MDSCs could improve the therapeutic efficacy of BM transplantation in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.